Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Niclosamide is an oral anthelmintic agent indicated for the treatment of tapeworm and other intestinal parasitic infections. It is administered as a chewable tablet and works by disrupting the energy metabolism of parasites, causing their expulsion from the GI tract. This is a pre-launch NDA product sponsored by R-Pharm US.
Pre-Launch
Pre-launch stage presents opportunity to build market position in a niche parasitic disease space; early-stage team formation likely underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
Niclosamide In Moderate COVID-19
Started Jan 2022
0COVID
Niclosamide in COVID-19
Started Jan 2022
0Covid19
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
Started Sep 2021
4 enrolled
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Started Apr 2021
166 enrolled
Covid19
Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat
Started Feb 2021
4 enrolled
Covid19
Worked on NICLOCIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.